Dosing schedule

KISQALI offers patients simple, once-daily dosing¹

KISQALI in combination with an AI for premenopausal and postmenopausal women¹

• Please refer to the summary of product characteristics for the recommended dose of the chosen AI.
• In premenopausal women, an LHRH agonist should be administered according to current clinical practice guidelines when given with KISQALI.
• Treatment of pre- and perimenopausal women with Kisqali plus AI should also include an LHRH agonist in accordance with local clinical practice.

KISQALI in combination with fulvestrant for postmenopausal women¹

• When given with KISQALI, the recommended dose of fulvestrant is 500 mg, administered on Days 1, 15 and 29, and once monthly thereafter. Please refer to the summary of product characteristics for fulvestrant for additional details.

Indication: KISQALI is indicated for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist.¹

AI, aromatase inhibitor; LHRH, luteinising hormone-releasing hormone.

References

1. KISQALI^® (ribociclib) Summary of Product Characteristics.
2. Fulvestrant Summary of Product Characteristics.